Our scientific foundation
Science is at the heart of BioDrug
Co-founded by Professor Vladimír Oleár, an expert in epidemiology, vaccinology and immunology, BioDrug combines scientific expertise, clinical development and regulatory capabilities to support pharmaceutical and biotechnology companies entering European markets.
Our mission is to turn scientific innovation into better access to medicines for patients.
Central and Eastern Europe is a fragmented pharmaceutical landscape. Each country has its own healthcare system, regulatory authorities, reimbursement mechanisms, medical practices and scientific decision-makers.
This diversity creates significant challenges for pharmaceutical and biotechnology companies, particularly those without a local presence or sufficient resources to manage multiple national markets.
BioDrug transforms this complexity into opportunity.
Through a coordinated regional platform, we simplify access to scientific experts, key opinion leaders, university hospitals and healthcare decision-makers, offering international partners one regional point of contact across multiple markets.
Regional understanding
Central Europe.
One region, multiple complexities.
Connected expertise
Our Scientific & Medical Platform
BioDrug connects scientific expertise with clinical development and market access through three complementary areas.
Scientific & Medical Advisory Boards
Connecting companies with recognised regional and national experts.
Scientific Publications & Medical Exchange
Supporting scientific communication, publications and expert consultations.
Clinical Development
Facilitating clinical research and evidence generation through reliable university and contract research organisation (CRO) partners who conduct the studies.
Our scientific track record
Scientific Publications
Our scientific foundation is supported by Professor Oleár’s contributions to epidemiology, immunology and vaccinology, including the following selected works.
- 2026
The Booster Effect in Tuberculosis Tests for PPD Tuberculin, IGRA, and SIILTIBCY – Mechanism and Clinical Relevance
- 2026
Current Vaccines and Prospects for the Development of New Vaccines Against Tick-Borne Encephalitis
- 2025
The Role of Artificial Intelligence in Epidemiology
- 2022
SARS-CoV-2 Vaccines: Options and Limitations for Their Use
- 2019
Factors Influencing Persistence of Diphtheria Immunity and Immune Response to a Booster Dose in Healthy Slovak Adults
- 2018
Predictors of the Immune Response to Booster Immunisation Against Tetanus in Czech Healthy Adults
English titles are provided for accessibility; some linked articles are in Slovak or Czech. External publication and registry links open in a new tab.
Clinical development & evidence
Clinical Studies
Clinical research through trusted partners. BioDrug works with reliable academic institutions and specialised clinical research organisations (CROs) that conduct clinical studies. We do not conduct studies in-house. Through these collaborations, BioDrug has contributed to European comparative non-inferiority vaccine studies and supported evidence generation.
Tetanus & diphtheria
Comparative booster-immunisation study in healthy adults.
View study record ↗Tetanus
Comparative booster-immunisation study in healthy adults.
View study results ↗From science to patients
More than a distributor.
Your scientific, clinical and commercial gateway to Europe.
BioDrug provides an integrated platform connecting scientific expertise, clinical development, regulatory affairs and market access.
We help pharmaceutical and biotechnology companies strengthen the clinical and scientific foundations of their medicines and expand their opportunities to enter new markets.
Together for better health
Let’s advance science together.
Partner with BioDrug to bring innovative medicines closer to patients.
